Piperacillin-Tazobactam GM Test Impact

### Conclusion Intravenous piperacillin-tazobactam is known to cause **false-positive serum galactomannan (GM) results**, but the retrieved evidence does not specifically address its effect on **bronchoalveolar lavage (BAL) fluid GM testing**. The documented false-positive phenomenon is primarily associated with serum assays, and formulation changes have been implemented to mitigate this issue. --- ### Clinical Evidence & Efficacy #### False-Positive GM: Serum vs. BAL - **Serum GM**: The association between intravenous piperacillin-tazobactam and false-positive serum GM results is well-documented in the literature. The British HIV Association (BHIVA) 2024 guidelines explicitly note that false-positive results may occur in individuals receiving piperacillin-tazobactam [1]. Multiple studies cited in the NCCN guidelines (Version 1.2024) corroborate this finding, including reports by Sulahian et al. (2003) and Walsh et al. (2004) [2]. - **BAL GM**: The retrieved evidence does **not** provide specific data on whether intravenous piperacillin-tazobactam directly causes false-positive results in BAL fluid GM testing. The BHIVA guidelines discuss BAL GM testing in the context of chronic pulmonary aspergillosis and subacute invasive aspergillosis, but do not list piperacillin-tazobactam as a known interferent for BAL specimens [1]. #### Mitigating Factors - **Formulation Changes**: The BHIVA guidelines note that changes to the formulation of piperacillin-tazobactam have been made to reduce the likelihood of false-positive results [1]. A study by Vergidis et al. (2014), cited in the NCCN guidelines, specifically reported a reduction in false-positive serum GM results associated with the use of piperacillin-tazobactam in the United States following these formulation changes [2]. #### Diagnostic Utility of BAL GM - **Sensitivity in Non-Neutropenic Patients**: The BHIVA guidelines explain that serum GM has low sensitivity in patients without neutropenia, which is why BAL GM testing has particular utility in these settings [1]. - **Combination Testing**: For chronic pulmonary aspergillosis, BAL GM or PCR can be combined with *Aspergillus*-specific IgG. For subacute invasive aspergillosis, BAL GM or PCR can supplement other tests [1]. --- ### Critical Gaps The current retrieved evidence does not contain specific studies or guideline recommendations addressing the impact of intravenous piperacillin-tazobactam on **BAL fluid GM test results**. The documented false-positive phenomenon is primarily described for serum assays. While it is biologically plausible that the drug or its metabolites could be present in the alveolar lining fluid and potentially interfere with the BAL assay, this is not confirmed by the available sources. --- ### Conclusion Based on the retrieved evidence, the known interference of intravenous piperacillin-tazobactam with GM testing is specifically documented for **serum** samples. There is **no direct evidence** in the provided literature to confirm or refute a similar effect on **BAL fluid** GM testing. Clinicians should be aware of the serum false-positive risk, but the impact on BAL specimens remains an area where specific data are lacking. --- *This analysis is based on retrieved literature and is intended for clinical reference. Clinical decisions should consider the full patient context and verify against the most current product labeling and institutional guidelines.*